Form 4: Dyne Therapeutics Director Dirk Kersten Reports Stock Sale

Director Dirk Kersten reports the sale of 1,577 shares of Dyne Therapeutics (DYN) common stock at an average price of $35.03.

Summary

• On September 5, 2024, Dirk Kersten, a director of Dyne Therapeutics, Inc. (DYN), reported the sale of 1,577 shares of common stock.
• The sale was executed at a weighted average price of $35.03 per share, with individual transactions ranging from $35.00 to $35.09.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on April 9, 2024.
• Following the transaction, Kersten indirectly beneficially owns 398,423 shares through FCF IV and 5,795,364 shares through ForDyne B.V.
• Kersten disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a stock sale by a director. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and are closely watched by investors for signals about the company's prospects.

Stakeholder Impact

• The stock sale by a director could be perceived negatively by some shareholders, although the sale was conducted under a pre-arranged trading plan.

Key Dates